One way to reconcile these conflicting observations is to accept the histiocytic or monocytic origin of giant cells in myocarditis and view the occasional presence of myocardial constituents to be a result of phagocytosis of myocytes by the macrophages. Even with these assumptions, however, the pathogenic mechanisms responsible for giant cell myocarditis remain to be elucidated. Because the disease has been seen in association with numerous conditions known to be due to disordered immunity (such as ulcerative colitis, myasthenia gravis, systemic lupus erythematosus, myositis, Sjdgren's syndrome, giant cell arteritis, thymoma, dermatomyositis, pernicious anemia, and chronic active hepatitis), it seems almost certain that giant cell myocarditis has an autoimmune etiology. Perhaps it is an unusually aggressive form of lymphocytic myocarditis, the aggressiveness accounting for appearance of giant cells. Even if this speculation were correct, the finding of giant cells on biopsy should trigger a much more assertive clinical response than the finding of lymphocytes alone.
A few more points regarding the study by Davidoff and colleagues' should be made. Although they provided a rationale for combining cases with and without systemic sarcoidosis, it would be incorrect to assume that the two groups are really clinically equivalent, or that they have the same etiology. Most previous authors3,8-10 have separated the two disorders. The increased statistical power Davidoff et al gained by grouping the two diseases might serve to misinform more than clarify. In this regard, it might be especially important to remember that the response of cardiac sarcoidosis to immunosuppressive therapy has been shown to be impressive,11 while responses of giant cell myocarditis are less so. Uncertainty about the use of immunosuppression in the latter condition should not discourage clinicians from its application in the former.
Though they suggest it, Davidoff et all are not providing a natural history study of giant cell myocarditis. Nine of the 10 subjects received immunosuppressive therapy, and many received additional therapies such as pacemaker implantation, pharmacological treatment of congestive heart failure, and cardiac transplantation. Thus, a 50% actuarial survival at 4 years probably does not accurately depict the natural course of this disease.
There are several points that deserve emphasis in the article by Davidoff and associates.1 Both lymphocytic and giant cell myocarditis can be detected by endomyocardial biopsy. They are among the most common of six distinct types of myocarditis. The former is relatively benign, so that potentially risky therapy need not be applied urgently, while the latter is an aggressive condition and should be treated promptly. Research is needed to further define pathogenesis and treatment of both disorders.
